Publication Name	World Journal of Gastroenterology
Manuscript ID	3639
Country	United States

Received	2013-05-11 10:26
Peer-Review Started	2013-05-11 13:46
To Make the First Decision	2013-06-09 10:06
Return for Revision	2013-06-20 11:07
Revised	2013-06-29 03:15
Second Decision	2013-08-06 08:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-08-06 17:35
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-08-29 12:18
Publish the Manuscript Online	2013-09-14 11:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure
Manuscript Source	Invited Manuscript
All Author List	Monil Shah, Laura Sandler, Vishwas Rai, Charu Sharma and Lakshmi Raghavan
Funding Agency and Grant Number	Funding Agency Grant Number Ventrus Biosciences, Inc., New York, NY, United States
Corresponding Author	Monil Shah, PharmD, MBA, Ventrus Biosciences, Inc., 99 Hudson Street, 5th Floor, New York, NY 10013, United States. mshah@ventrusbio.com
Key Words	Anal fissure; Pharmacy compounding; Topical diltiazem; Formulation potency; Content uniformity
Core Tip	The use of topical 2% diltiazem hydrochloride for treating anal fissures is supported by multiple clinical trials and is recommended in published practice parameters. As no commercially manufactured formulation of topical 2% diltiazem has been approved yet by the Food and Drug Administration for the treatment of anal fissure, prescriptions for the medication need to be extemporaneously compounded by retail pharmacies. Employing high-performance liquid chromatography analysis of topical 2% diltiazem formulations compounded by a sampling of pharmacies, we found a notable trend toward lack of content uniformity and misbranding of potency, suggesting that many patients might not receive the anticipated relief of anal-fissure pain.
Publish Date	2013-09-14 11:17
Citation	Shah M, Sandler L, Rai V, Sharma C, Raghavan L. Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure. World J Gastroenterol 2013; 19(34): 5645-5650
URL	http://www.wjgnet.com/1007-9327/full/v19/i34/5645.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i34.5645

Full Article (PDF)	WJG-19-5645.pdf
Manuscript File	3639-Review.docx
Answering Reviewers	3639-Answering reviewers.pdf
Copyright License Agreement	3639-Copyright assignment.pdf
Peer-review Report	3639-Peer review(s).pdf
Scientific Editor Work List	3639-Scientific editor work list.doc